cgs 22652 has been researched along with thromboxane b2 in 1 studies
Studies (cgs 22652) | Trials (cgs 22652) | Recent Studies (post-2010) (cgs 22652) | Studies (thromboxane b2) | Trials (thromboxane b2) | Recent Studies (post-2010) (thromboxane b2) |
---|---|---|---|---|---|
10 | 0 | 0 | 7,483 | 715 | 485 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cohen, DS; Dotson, R; Mathis, J; Olson, RW; Webb, RL | 1 |
1 other study(ies) available for cgs 22652 and thromboxane b2
Article | Year |
---|---|
Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Caprylates; Coronary Circulation; Coronary Thrombosis; Dinoprostone; Dogs; Hemodynamics; Indoles; Male; Myocardial Reperfusion; Phenylacetates; Platelet Activation; Platelet Aggregation Inhibitors; Pyridines; Receptors, Thromboxane; Streptokinase; Sulfonamides; Thromboxane B2; Thromboxane-A Synthase; Thromboxanes | 1993 |